ZA200700071B - Combinations of statins with bronchodilators - Google Patents

Combinations of statins with bronchodilators Download PDF

Info

Publication number: ZA200700071B
Authority: ZA; South Africa
Prior art keywords: solvate; active ingredient; salt; pharmaceutically acceptable; acceptable salt
Prior art date: 2004-07-15

Application number

ZA200700071A

Other languages

English (en)

Inventor

Lindmark Bertil

Thoren Anders Ingemar

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-15

Filing date

2007-01-02

Publication date

2008-04-30

2007-01-02 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-04-30 Publication of ZA200700071B publication Critical patent/ZA200700071B/en

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims description 48
229940124630 bronchodilator Drugs 0.000 title claims description 19
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title description 25
239000000168 bronchodilator agent Substances 0.000 title description 3
150000003839 salts Chemical class 0.000 claims description 71
239000012453 solvate Substances 0.000 claims description 67
239000004480 active ingredient Substances 0.000 claims description 48
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 32
-1 as bromide) Chemical compound 0.000 claims description 24
238000011282 treatment Methods 0.000 claims description 21
229960000672 rosuvastatin Drugs 0.000 claims description 19
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 19
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 18
229960004436 budesonide Drugs 0.000 claims description 17
239000003862 glucocorticoid Substances 0.000 claims description 17
229960002848 formoterol Drugs 0.000 claims description 16
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 13
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 13
229960005370 atorvastatin Drugs 0.000 claims description 13
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 11
239000000556 agonist Substances 0.000 claims description 11
208000023504 respiratory system disease Diseases 0.000 claims description 8
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
239000000812 cholinergic antagonist Substances 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 6
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical group C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 5
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 5
229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 5
229960003728 ciclesonide Drugs 0.000 claims description 5
229960000257 tiotropium bromide Drugs 0.000 claims description 5
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
229960005110 cerivastatin Drugs 0.000 claims description 4
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
229960002965 pravastatin Drugs 0.000 claims description 4
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 4
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 4
229960004017 salmeterol Drugs 0.000 claims description 4
229960002855 simvastatin Drugs 0.000 claims description 4
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 4
229940110309 tiotropium Drugs 0.000 claims description 4
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 4
229960004045 tolterodine Drugs 0.000 claims description 4
OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 4
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 4
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 3
IUIYEHXOIMMQJY-NGXOUOCZSA-N 60135-22-0 Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)C(OC)OC)[C@@]2(C)C[C@@H]1O IUIYEHXOIMMQJY-NGXOUOCZSA-N 0.000 claims description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 3
229950002998 flumoxonide Drugs 0.000 claims description 3
229960003765 fluvastatin Drugs 0.000 claims description 3
229960004844 lovastatin Drugs 0.000 claims description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
229950009116 mevastatin Drugs 0.000 claims description 3
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 3
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 3
230000000241 respiratory effect Effects 0.000 claims description 3
OJRPWVDDBGJONP-PQUGYNIPSA-N s-[(3r)-2-oxooxolan-3-yl] (6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)S[C@@H]1CCOC1=O OJRPWVDDBGJONP-PQUGYNIPSA-N 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
229950001256 zoticasone Drugs 0.000 claims description 3
DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 claims description 2
ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims description 2
HOAKOHHSHOCDLI-TUFAYURCSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 claims description 2
XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 claims description 2
ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims description 2
229960003060 bambuterol Drugs 0.000 claims description 2
229940092705 beclomethasone Drugs 0.000 claims description 2
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
229950001167 butixocort Drugs 0.000 claims description 2
229960002677 darifenacin Drugs 0.000 claims description 2
HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 2
JTXYEERBIZXLJC-DCJXKKNWSA-N ethyl (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCC)(O)[C@@]1(C)C[C@@H]2O JTXYEERBIZXLJC-DCJXKKNWSA-N 0.000 claims description 2
229960002978 fesoterodine Drugs 0.000 claims description 2
DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims description 2
229960000676 flunisolide Drugs 0.000 claims description 2
229960002714 fluticasone Drugs 0.000 claims description 2
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
229960000193 formoterol fumarate Drugs 0.000 claims description 2
229960002462 glycopyrronium bromide Drugs 0.000 claims description 2
229950005396 imidafenacin Drugs 0.000 claims description 2
SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 claims description 2
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 2
229960001888 ipratropium Drugs 0.000 claims description 2
229960001798 loteprednol Drugs 0.000 claims description 2
YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 2
229960001664 mometasone Drugs 0.000 claims description 2
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 claims description 2
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims description 2
229960000797 oxitropium Drugs 0.000 claims description 2
229960002797 pitavastatin Drugs 0.000 claims description 2
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 2
229960005205 prednisolone Drugs 0.000 claims description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
229960004618 prednisone Drugs 0.000 claims description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 2
229950004432 rofleponide Drugs 0.000 claims description 2
FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 2
229960003855 solifenacin Drugs 0.000 claims description 2
229950001669 tipredane Drugs 0.000 claims description 2
229960005294 triamcinolone Drugs 0.000 claims description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical group OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 1
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 claims 1
XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 claims 1
108090001069 Chymopapain Proteins 0.000 claims 1
101100238304 Mus musculus Morc1 gene Proteins 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
230000005713 exacerbation Effects 0.000 description 14
RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 13
230000000694 effects Effects 0.000 description 12
229960003610 formoterol fumarate dihydrate Drugs 0.000 description 12
239000000203 mixture Substances 0.000 description 9
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 8
229940035073 symbicort Drugs 0.000 description 8
NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000000843 powder Substances 0.000 description 6
102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
239000000443 aerosol Substances 0.000 description 5
208000006673 asthma Diseases 0.000 description 5
229960000289 fluticasone propionate Drugs 0.000 description 5
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
230000004199 lung function Effects 0.000 description 5
230000000391 smoking effect Effects 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
150000008331 benzenesulfonamides Chemical class 0.000 description 4
230000007423 decrease Effects 0.000 description 4
AKYNJTFOHFQPEM-JRLZQBLDSA-N foradil-combi Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O AKYNJTFOHFQPEM-JRLZQBLDSA-N 0.000 description 4
229940021598 formoterol and budesonide Drugs 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 3
229940125369 inhaled corticosteroids Drugs 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
208000037920 primary disease Diseases 0.000 description 3
201000003068 rheumatic fever Diseases 0.000 description 3
229960005018 salmeterol xinafoate Drugs 0.000 description 3
239000003826 tablet Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 2
208000000884 Airway Obstruction Diseases 0.000 description 2
206010001889 Alveolitis Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010006458 Bronchitis chronic Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
201000009594 Systemic Scleroderma Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
230000003182 bronchodilatating effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000007451 chronic bronchitis Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
DYDNPESBYVVLBO-UHFFFAOYSA-N formanilide Chemical class O=CNC1=CC=CC=C1 DYDNPESBYVVLBO-UHFFFAOYSA-N 0.000 description 2
SYCWERNQGSKYAG-QVRIGTRMSA-N hydron;8-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1h-quinolin-2-one;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 SYCWERNQGSKYAG-QVRIGTRMSA-N 0.000 description 2
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
229960004078 indacaterol Drugs 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000036971 interstitial lung disease 2 Diseases 0.000 description 2
229940002661 lipitor Drugs 0.000 description 2
229940125389 long-acting beta agonist Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229960002744 mometasone furoate Drugs 0.000 description 2
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
229940124624 oral corticosteroid Drugs 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
230000005586 smoking cessation Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
GBTODAKMABNGIJ-VWLOTQADSA-N 3-[4-[6-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexoxy]butyl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CCCCOCCCCCCNC[C@H](O)C=2C=C(CO)C(O)=CC=2)=C1 GBTODAKMABNGIJ-VWLOTQADSA-N 0.000 description 1
XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010023226 Joint related signs and symptoms Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
108010028275 Leukocyte Elastase Proteins 0.000 description 1
102000016799 Leukocyte elastase Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
102100027998 Macrophage metalloelastase Human genes 0.000 description 1
101710187853 Macrophage metalloelastase Proteins 0.000 description 1
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940054051 antipsychotic indole derivative Drugs 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229950010713 carmoterol Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
238000010411 cooking Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
229950009769 etabonate Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000002615 fibrolytic effect Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
208000018875 hypoxemia Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
231100000516 lung damage Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000011422 pharmacological therapy Methods 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1
150000008584 quinuclidines Chemical class 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229950000339 xinafoate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200700071A 2004-07-15 2007-01-02 Combinations of statins with bronchodilators ZA200700071B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0415789.7A GB0415789D0 (en)	2004-07-15	2004-07-15	Novel combination

Publications (1)

Publication Number	Publication Date
ZA200700071B true ZA200700071B (en)	2008-04-30

Family

ID=32893577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200700071A ZA200700071B (en)	2004-07-15	2007-01-02	Combinations of statins with bronchodilators

Country Status (14)

Country	Link
US (1)	US20080004247A1 (no)
EP (1)	EP1773319A1 (no)
JP (1)	JP2008506674A (no)
CN (1)	CN1984653A (no)
AU (1)	AU2005263883A1 (no)
BR (1)	BRPI0513283A (no)
CA (1)	CA2573393A1 (no)
GB (1)	GB0415789D0 (no)
IL (1)	IL180423A0 (no)
MX (1)	MX2007000424A (no)
NO (1)	NO20070651L (no)
RU (1)	RU2007101518A (no)
WO (1)	WO2006008437A1 (no)
ZA (1)	ZA200700071B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080029962A (ko)	2005-06-02	2008-04-03	더 리젠츠 오브 더 유니버시티 오브 콜로라도	프로스타사이클린 유사체의 용도
WO2008001752A1 (en) *	2006-06-29	2008-01-03	Daiichi Sankyo Company, Limited	Treatment of chronic obstructive pulmonary disease by statin
EP2359826B1 (en) *	2006-07-05	2013-10-30	Takeda GmbH	Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
EP1894568A1 (en) *	2006-08-31	2008-03-05	Novartis AG	Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2008088617A1 (en) *	2006-12-04	2008-07-24	Regents Of The University Of Colorado	Treatment of copd
US20150174157A1 (en) *	2007-06-15	2015-06-25	Kaohsiung Medical University	INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY
WO2011125763A1 (ja) *	2010-03-31	2011-10-13	小野薬品工業株式会社	手足症候群の予防および／または治療剤
JP4983989B2 (ja) *	2010-03-31	2012-07-25	小野薬品工業株式会社	手足症候群の予防および治療剤
BR112013001119A2 (pt)	2010-07-16	2016-05-24	Cipla Ltd	composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
CN104363910A (zh) *	2012-03-14	2015-02-18	日本株式会社Ltt生物医药	慢性阻塞性肺疾病改善剂
MX2015013845A (es) *	2013-04-01	2016-05-09	Pulmatrix Inc	Polvos secos de tiotropio.
AU2014262621B2 (en)	2013-05-08	2018-03-01	Baylor College Of Medicine	STAT6 inhibitors
CN106413759B (zh) *	2014-03-28	2022-02-22	列日大学	用于治疗和预防肺部炎症的包含环糊精和布地奈德衍生物的组合物
US11069054B2 (en)	2015-12-30	2021-07-20	Visiongate, Inc.	System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy
EP3732075A4 (en)	2018-03-01	2021-03-10	Comfort Concepts, Llc	SEAT PADDING WITH WOVEN COVER
JP2021533190A (ja) *	2018-07-31	2021-12-02	タンウェンTAN, Wen	ＬＤＬコレステロールの細胞内クリアランスを増強しかつスタチンとの併用療法で効力を高めかつ副作用を減らすための、カルバメートβフェニルエタノールアミン類似体の新規使用法
CN109498625B (zh) *	2018-12-29	2021-04-16	温州医科大学附属第一医院	一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
CN115337311B (zh) *	2022-09-26	2023-05-09	南京恒道医药科技股份有限公司	一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5270305A (en) *	1989-09-08	1993-12-14	Glaxo Group Limited	Medicaments
US20010006656A1 (en) *	1999-02-17	2001-07-05	University Of Washington	Methods and compositions for inhibiting inflammation associated with pulmonary disease
CA2399396A1 (en) *	2000-02-10	2001-08-16	Yasuo Sugiyama	Tnf- .alpha. inhibitors
US20050119330A1 (en) *	2003-03-17	2005-06-02	Kao Peter N.	Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases

2004
- 2004-07-15 GB GBGB0415789.7A patent/GB0415789D0/en not_active Ceased
2005
- 2005-06-20 US US11/571,869 patent/US20080004247A1/en not_active Abandoned
- 2005-06-20 AU AU2005263883A patent/AU2005263883A1/en not_active Abandoned
- 2005-06-20 CA CA002573393A patent/CA2573393A1/en not_active Abandoned
- 2005-06-20 MX MX2007000424A patent/MX2007000424A/es not_active Application Discontinuation
- 2005-06-20 RU RU2007101518/15A patent/RU2007101518A/ru unknown
- 2005-06-20 EP EP05752046A patent/EP1773319A1/en not_active Withdrawn
- 2005-06-20 JP JP2007520874A patent/JP2008506674A/ja active Pending
- 2005-06-20 CN CNA2005800238019A patent/CN1984653A/zh active Pending
- 2005-06-20 WO PCT/GB2005/002413 patent/WO2006008437A1/en not_active Ceased
- 2005-06-20 BR BRPI0513283-5A patent/BRPI0513283A/pt not_active Application Discontinuation
2006
- 2006-12-28 IL IL180423A patent/IL180423A0/en unknown
2007
- 2007-01-02 ZA ZA200700071A patent/ZA200700071B/en unknown
- 2007-02-05 NO NO20070651A patent/NO20070651L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX2007000424A (es)	2007-03-07
US20080004247A1 (en)	2008-01-03
JP2008506674A (ja)	2008-03-06
EP1773319A1 (en)	2007-04-18
CA2573393A1 (en)	2006-01-26
RU2007101518A (ru)	2008-08-20
GB0415789D0 (en)	2004-08-18
WO2006008437A1 (en)	2006-01-26
NO20070651L (no)	2007-02-05
IL180423A0 (en)	2008-03-20
AU2005263883A1 (en)	2006-01-26
BRPI0513283A (pt)	2008-05-06
CN1984653A (zh)	2007-06-20

Publication	Publication Date	Title
ZA200700071B (en)	2008-04-30	Combinations of statins with bronchodilators
US11975005B2 (en)	2024-05-07	Treatment of respiratory diseases
EP1834643A2 (en)	2007-09-19	Novel medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
CN101502500A (zh)	2009-08-12	含有β2-激动剂的溶液的加压计量吸入器
JP2014525471A (ja)	2014-09-29	咳および咳発作の治療
JP2022520990A (ja)	2022-04-04	呼吸器疾患の治療の方法
AU2003292120B2 (en)	2010-01-21	New synergistic combination comprising roflumilast and formoterol
US20070167496A1 (en)	2007-07-19	Roflumilast and glycopyrronium combination
FI4199922T3 (fi)	2024-12-05	(1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
WO2006123125A1 (en)	2006-11-23	Combinations of statins with glucocorticosteroids
EP4188327B1 (en)	2025-05-28	Combination therapy for inhalation administration
AU2003288169B8 (en)	2010-08-26	Synergistic combination comprising roflumilast and (R,R) -formoterol
JP2019519572A (ja)	2019-07-11	Ｃｏｐｄを処置するための組成物および方法
KR20070031392A (ko)	2007-03-19	스타틴과 기관지확장제와의 조합물
WO2006117534A2 (en)	2006-11-09	New use
WO2010071582A1 (en)	2010-06-24	Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
MXPA06008938A (en)	2006-12-13	The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
HK1081862B (en)	2009-05-29	Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1087009B (en)	2008-07-25	Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
HK1081861B (en)	2009-05-29	New synergistic combination comprising roflumilast and formoterol